Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma

Table 3

Univariate and multivariate analysis of overall survival in HCC patients.

Clinicopathologic parameters	Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)
Age (<60 vs. ≥60)	1.067 (0.514-2.216)	0.861
Gender (female vs. male)	0.541 (0.231-1.266)	0.157
Hepatitis B (negative vs. positive)	0.895 (0.365-2.191)	0.808
AFP (<400 vs. ≥400)	1.398 (0.682-2.866)	0.360
Cirrhosis (present vs. absent)	1.208 (0.575-2.540)	0.618
Microvascular invasion (present vs. absent)	1.791 (0.540-5.938)	0.341
Tumor differentiation (low vs. high/moderate)	0.876 (0.424-1.809)	0.720
Capsular invasion (present vs. absent)	2.175 (1.063-4.452)	0.033	1.436 (0.662-3.116)	0.360
Tumor diameter (<5 cm vs. ≥5 cm)	3.480 (1.210-10.005)	0.021	1.952 (0.620-6.143)	0.253
Multiple lesions (present vs. absent)	2.410 (1.140-5.095)	0.021	1.125 (0.429-2.952)	0.810
Vessel carcinoma embolus (present vs. absent)	2.075 (0.949-4.538)	0.068	2.047 (0.898-4.665)	0.088
TNM stage (I~II vs. III~IV)	3.061 (1.480-6.331)	0.003	2.637 (1.263-5.507)	0.010
SNORA71A expression (low vs. high)	0.257 (0.114-0.580)	0.001	0.289 (0.127-0.657)	0.003

AFP = alpha fetal protein; TNM = tumor-node-metastasis; HR = hazard ratio; was considered statistically significant.